Zealand Pharma (Denmark) Today
| ZEAL Stock | DKK 565.00 2.50 0.44% |
PerformanceVery Weak
| Odds Of DistressLow
|
Zealand Pharma is selling at 565.00 as of the 21st of March 2025; that is 0.44 percent down since the beginning of the trading day. The stock's open price was 567.5. Zealand Pharma has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Zealand Pharma AS, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. The company has 51.28 M outstanding shares. More on Zealand Pharma AS
Moving together with Zealand Stock
Moving against Zealand Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Zealand Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Zealand Pharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Zealand Pharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Zealand Pharma AS (ZEAL) is traded on Copenhagen Exchange in Denmark and employs 203 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 11.16 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Zealand Pharma's market, we take the total number of its shares issued and multiply it by Zealand Pharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Zealand Pharma AS operates under Healthcare sector and is part of Biotechnology industry. The entity has 51.28 M outstanding shares.
Zealand Pharma AS has accumulated about 1.28 B in cash with (1.21 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 29.66.
Check Zealand Pharma Probability Of Bankruptcy
Ownership AllocationZealand Pharma AS retains a total of 51.28 Million outstanding shares. Over half of Zealand Pharma's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Zealand Pharma AS. Please watch out for any change in the institutional holdings of Zealand Pharma AS as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Zealand Ownership Details
Zealand Pharma AS Risk Profiles
Although Zealand Pharma's alpha and beta are two of the key measurements used to evaluate Zealand Pharma's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.0 | |||
| Standard Deviation | 5.73 | |||
| Variance | 32.88 | |||
| Risk Adjusted Performance | (0.04) |
Zealand Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Zealand Pharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run FinTech Suite Now
FinTech SuiteUse AI to screen and filter profitable investment opportunities |
| All Next | Launch Module |
Zealand Pharma Corporate Management
Elected by the shareholders, the Zealand Pharma's board of directors comprises two types of representatives: Zealand Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zealand. The board's role is to monitor Zealand Pharma's management team and ensure that shareholders' interests are well served. Zealand Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zealand Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Henriette Wennicke | Chief Officer | Profile | |
| Lani Morvan | Investor Officer | Profile | |
| Adam MD | Pres CEO | Profile | |
| Hanne Bak | RD Director | Profile | |
| Mads Kronborg | Head Communication | Profile | |
| Ravinder Chahil | Sr Counsel | Profile | |
| Christina Bredal | VP Organization | Profile |
Other Information on Investing in Zealand Stock
Zealand Pharma financial ratios help investors to determine whether Zealand Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.